<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936464</url>
  </required_header>
  <id_info>
    <org_study_id>12791</org_study_id>
    <nct_id>NCT04936464</nct_id>
  </id_info>
  <brief_title>Transcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence</brief_title>
  <acronym>TTeNS</acronym>
  <official_title>Transcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence: A Sham-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urogynecologic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, double-blinded, randomized controlled trial evaluating the efficacy&#xD;
      of TTNS versus a sham intervention. Both interventions will be performed by participants in&#xD;
      their homes after standardized instruction. The primary outcome is a comparison of the mean&#xD;
      change in OAB-q scores before and after treatment between the intervention and control&#xD;
      groups. Changes in the number of urgency incontinence episodes and an estimation of cost&#xD;
      effectiveness will additionally be measured. Intention to treat analysis will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the efficacy of a 12-week course of TTNS in reducing urgency urinary incontinence (UUI) symptom bother in the intervention versus sham group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voiding diary</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the efficacy of a 12-week course of TTNS in reducing the frequency of UUI episodes in the intervention versus sham group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incremental cost-effectiveness ratio (ICER)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the cost effectiveness of a 12-week course of home-based TTNS therapy using an ICER calculated from the sum of direct medical and indirect non-medical costs relative to health-related quality of life, as measured by the European Quality of Life-5 Dimensions index.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Urge Incontinence</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous tibial nerve stimulation (TTNS)</intervention_name>
    <description>TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous electrical stimulation (TENS)</intervention_name>
    <description>The sham intervention is designed to appear almost identical to the TTNS intervention.</description>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 6 episodes urgency incontinence on 3-day voiding diary&#xD;
&#xD;
          -  Duration of symptoms ≥ 3 months&#xD;
&#xD;
          -  Off antimuscarinic or 3-adrenoreceptor agonist therapy for 2 weeks&#xD;
&#xD;
          -  No known neurologic disease&#xD;
&#xD;
          -  Ability to complete home sessions and clinic follow up&#xD;
&#xD;
          -  Ability to complete voiding diaries&#xD;
&#xD;
          -  Internet access and proficiency&#xD;
&#xD;
          -  English or Spanish-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Known or suspected urinary retention&#xD;
&#xD;
          -  Symptomatic urinary tract infection unresolved at the time of randomization&#xD;
&#xD;
          -  Recurrent urinary tract infection (≥ 3/12 months)&#xD;
&#xD;
          -  Bladder pain syndrome&#xD;
&#xD;
          -  Known or suspected advanced (stage III or IV) pelvic organ prolapse&#xD;
&#xD;
          -  Neurogenic bladder&#xD;
&#xD;
          -  Current or prior bladder malignancy&#xD;
&#xD;
          -  Current or previous use of bladder Botox injections, percutaneous tibial nerve&#xD;
             stimulation, or sacral neuromodulation&#xD;
&#xD;
          -  Pacemaker or other implantable device&#xD;
&#xD;
          -  Disease affecting lower extremities&#xD;
&#xD;
          -  Bilateral metallic lower limb implant&#xD;
&#xD;
          -  Incarceration&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Trial is open to biologically female participants only as this is the target population of interest.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nemi M Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Diego/Kaiser Permanente San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nemi M Shah, MD</last_name>
    <phone>(619) 221-0350</phone>
    <email>nemi.m.shah@kp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shawn A Menefee, MD</last_name>
    <phone>(619) 221-0350</phone>
    <email>shawn.a.menefee@kp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaiser Permanente San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nemi M Shah, MD</last_name>
      <phone>619-221-0350</phone>
      <email>nemi.m.shah@kp.org</email>
    </contact>
    <contact_backup>
      <last_name>Shawn A Menefee, MD</last_name>
      <phone>(619) 221-0350</phone>
      <email>shawn.a.menefee@kp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nemi M Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tibial nerve stimulation</keyword>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>overactive bladder</keyword>
  <keyword>urgency urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

